Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.

Mark Ross MiddletonCheryl McAlpineVictoria K WoodcockPhilippa CorrieJeffrey R InfanteNeil M StevenThomas R Jeffry EvansAlan AnthoneyAlexander N Shoushtari Omid HamidAvinash GuptaAntonella VardeuEmma LeachRevashnee NaidooSarah StanhopeSion LewisJacob HurstIta O'KellyMario Sznol

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

These data suggest that redirecting T cells using a gp100-targeting TCR/anti-CD3 bispecific fusion protein may provide benefit to patients with metastatic melanoma. Furthermore, the activity observed in these two molecularly disparate melanoma classes hints at the broad therapeutic potential of tebentafusp.

Keyphrases

immune response
regulatory t cells
cancer therapy
electronic health record
nk cells
big data
dendritic cells
inflammatory response
skin cancer
data analysis